You have full text access to this OnlineOpen article

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

  1. L. Pagano1,
  2. L. Fianchi1,
  3. R. Fanci2,
  4. A. Candoni3,
  5. M. Caira1,
  6. B. Posteraro1,
  7. M. Morselli4,
  8. C. G. Valentini1,
  9. G. Farina5,
  10. M. E. Mitra6,
  11. M. Offidani7,
  12. M. Sanguinetti1,
  13. M. E. Tosti8,
  14. A. Nosari9,
  15. G. Leone1,
  16. P. Viale3

Article first published online: 22 JUN 2009

DOI: 10.1111/j.1469-0691.2009.02832.x

Issue

Clinical Microbiology and Infection

Clinical Microbiology and Infection

Volume 16, Issue 3, pages 298–301, March 2010

Additional Information

How to Cite

Pagano, L., Fianchi, L., Fanci, R., Candoni, A., Caira, M., Posteraro, B., Morselli, M., Valentini, C. G., Farina, G., Mitra, M. E., Offidani, M., Sanguinetti, M., Tosti, M. E., Nosari, A., Leone, G. and Viale, P. (2010), Caspofungin for the treatment of candidaemia in patients with haematological malignancies. Clinical Microbiology and Infection, 16: 298–301. doi: 10.1111/j.1469-0691.2009.02832.x

Author Information

  1. 1

     Haematology and Microbiology Institutes, Catholic University, Rome

  2. 2

     Haematology Institute, University of Firenze, Firenze

  3. 3

     Haematology and Infectious Diseases Institutes, University of Udine, Udine

  4. 4

     Haematology Institute, University of Modena, Modena

  5. 5

     Haematology Department Catholic University Campobasso, Campobasso

  6. 6

     Haematology Institute, University of Palermo, Palermo

  7. 7

     Haematology Institute, University of Ancona, Ancona

  8. 8

     Epidemiologia Clinica Department, Istituto Superiore della Sanità, Rome

  9. 9

     Haematology Division and Transplant Unit, Niguarda Ca’ Grande Hospital, Milano, Italy

*Corresponding author and reprint requests: L. Pagano, Department of Haematology, Catholic University, Largo Francesco Vito, 1, I-00168 Rome, Italy E-mail: lpagano@rm.unicatt.it

Publication History

  1. Issue published online: 9 FEB 2010
  2. Article first published online: 22 JUN 2009
  3. Original Submission: 20 November 2008; Revised Submission: 25 February 2009; Accepted: 27 February 2009 Editor: E. Roilides

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (46K)

Keywords:

  • Candidaemia;
  • caspofungin;
  • leukaemia

Clin Microbiol Infect 2010; 16: 298–301

Abstract

This study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.

View Full Article (HTML) Get PDF (46K)